Inflammatory Bowel Disease: Pathogenesis, Causative Factors, Issues, Drug Treatment Strategies, and Delivery Approaches - PubMed (original) (raw)
Review
Inflammatory Bowel Disease: Pathogenesis, Causative Factors, Issues, Drug Treatment Strategies, and Delivery Approaches
Deependra Singh et al. Crit Rev Ther Drug Carrier Syst. 2015.
Abstract
Inflammatory bowel disease (IBD) is an incessant, reverting, inflammatory disorder of the gastrointestinal tract encompassing two entities, namely, Crohn's disease (CD) and ulcerative colitis (UC). Numerous protocols have been explored to treat these dreadful diseases, including the use of different IBD drugs with different modes of action and routes of administration. Constant progression in the development of newer formulations, chemical modifications, stimuli-responsive systems, and novel approaches using colloidal and cellular carriers have led to effective treatments of gastric inflammation. Colloidal carriers including vesicular and particulate systems such as liposomes, transferosomes, solid lipid nanoparticles, microspheres; cellular carriers including erythrocytes, macrophages, and recombinant bacteria; and other systems such as osmotic pressure and plug control release have gained unique positions as drug carriers. Here, we investigate IBD in terms of its pathogenesis, role of genetic factors, currently available treatment options and their modes of action, pharmacokinetics, marketed products, side effects of individual IBD drugs, recent developments, modifications in the delivery of various drugs through novel colloidal drug carriers, and future prospects.
Similar articles
- Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches.
Pradhan M, Singh D, Singh MR. Pradhan M, et al. J Control Release. 2013 Sep 28;170(3):380-95. doi: 10.1016/j.jconrel.2013.05.020. Epub 2013 Jun 13. J Control Release. 2013. PMID: 23770117 Review. - Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease.
Li X, Lu C, Yang Y, Yu C, Rao Y. Li X, et al. Biomed Pharmacother. 2020 Sep;129:110486. doi: 10.1016/j.biopha.2020.110486. Epub 2020 Jul 8. Biomed Pharmacother. 2020. PMID: 32768972 Review. - Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.
Takedatsu H, Mitsuyama K, Torimura T. Takedatsu H, et al. World J Gastroenterol. 2015 Oct 28;21(40):11343-52. doi: 10.3748/wjg.v21.i40.11343. World J Gastroenterol. 2015. PMID: 26525603 Free PMC article. Review. - Treatment of inflammatory bowel disease (IBD).
Pithadia AB, Jain S. Pithadia AB, et al. Pharmacol Rep. 2011;63(3):629-42. doi: 10.1016/s1734-1140(11)70575-8. Pharmacol Rep. 2011. PMID: 21857074 Review. - Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease.
Liu Y, Wang X, Hu CA. Liu Y, et al. Nutrients. 2017 Aug 23;9(9):920. doi: 10.3390/nu9090920. Nutrients. 2017. PMID: 28832517 Free PMC article. Review.
Cited by
- Amygdalin Alleviates DSS-Induced Colitis by Restricting Cell Death and Inflammatory Response, Maintaining the Intestinal Barrier, and Modulating Intestinal Flora.
Xu D, Xie Y, Cheng J, He D, Liu J, Fu S, Hu G. Xu D, et al. Cells. 2024 Mar 3;13(5):444. doi: 10.3390/cells13050444. Cells. 2024. PMID: 38474407 Free PMC article. - Sea Cucumber Peptides Ameliorate DSS-Induced Ulcerative Colitis: The Role of the Gut Microbiota, the Intestinal Barrier, and Macrophage Polarization.
Yu S, Guo H, Ji Z, Zheng Y, Wang B, Chen Q, Tang H, Yuan B. Yu S, et al. Nutrients. 2023 Nov 17;15(22):4813. doi: 10.3390/nu15224813. Nutrients. 2023. PMID: 38004208 Free PMC article. - Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives.
Chen M, Lan H, Jin K, Chen Y. Chen M, et al. Drug Deliv. 2023 Dec;30(1):2219427. doi: 10.1080/10717544.2023.2219427. Drug Deliv. 2023. PMID: 37288799 Free PMC article. - Precision Medicines for Retinal Lipid Metabolism-Related Pathologies.
Ana RD, Gliszczyńska A, Sanchez-Lopez E, Garcia ML, Krambeck K, Kovacevic A, Souto EB. Ana RD, et al. J Pers Med. 2023 Apr 5;13(4):635. doi: 10.3390/jpm13040635. J Pers Med. 2023. PMID: 37109021 Free PMC article. Review. - Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system.
Luo P, Li X, Gao Y, Chen Z, Zhang Q, Wang Z, Tian X. Luo P, et al. Front Pharmacol. 2022 Sep 13;13:904926. doi: 10.3389/fphar.2022.904926. eCollection 2022. Front Pharmacol. 2022. PMID: 36176442 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical